Cardiac Effects of Rosiglitazone in Male Wistar Rats

Rosiglitazone, a peroxisome proliferator-activated receptor g (PPARg) agonist of the thiazolidinedione class, is a major insulin-sensitizing drug widely used to treat type-2 diabetes. Rosiglitazone causes myocardial hypertrophy in rodents and increases the risk of cardiac events in man. To better characterize its cardiac effects, male Wistar rats were orally administered 0, 10 or 80 mg/kg/day rosiglitazone.罗格列酮（Rosiglitazone）属于噻唑烷二酮类过氧化物酶体增殖物激活受体g（peroxisome proliferator-activated receptor g，PPARg）激动剂，是临床广泛应用于2型糖尿病治疗的主流胰岛素增敏药物。罗格列酮可在啮齿类动物中诱导心肌肥厚，并增加人类心脏不良事件的发生风险。为更全面地表征其心脏相关效应，研究人员对雄性Wistar大鼠经口给予0、10或80 mg/kg/天的罗格列酮。